^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Depocyte (liposomal cytarabine)

    Associations

    News

    Trials
    Company:
    Leadiant Biosci, Mundipharma
    Drug class:
    DNA polymerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    Efficacy of EXPAREL vs. Bupivacaine (clinicaltrials.gov)
    P3, N=104, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Depocyte (liposomal cytarabine)
    28d
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    2ms
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    4ms
    Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ALK positive
    |
    cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim)
    5ms
    Efficacy of EXPAREL vs. Bupivacaine (clinicaltrials.gov)
    P3, N=104, Not yet recruiting, Emory University
    New P3 trial
    |
    Depocyte (liposomal cytarabine)
    7ms
    O-ICE: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (clinicaltrials.gov)
    P2, N=25, Recruiting, New York Medical College | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)
    7ms
    A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=22 --> 0 | Trial completion date: Dec 2033 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2031 --> Jul 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    sorafenib • cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    11ms
    Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2025 --> Apr 2030
    Trial completion date
    |
    Rituxan (rituximab) • cytarabine • bendamustine • Depocyte (liposomal cytarabine)
    1year
    A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2024 --> Dec 2025
    Trial initiation date
    |
    sorafenib • cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    over1year
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Dec 2025
    Trial completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    over1year
    IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov)
    P2, N=54, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed
    Trial completion
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Depocyte (liposomal cytarabine)
    over1year
    A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    sorafenib • cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)